The primary mission of Reprocell Technologies is to conduct scientific research
into reproductive DNA cloning technology to bring about births through
such technology in the interest of science and its relationship
to the advancement of the human condition. Reproductive DNA cloning
technology provides a new and vibrant reproductive choice, particularly
for those who may well have exhausted other reproductive methods.
Bringing about births from the tissues of living individuals allows
those who wish to procreate in this manner to have this reproductive
choice available. All testing and procedures for Reprocell Technologies will be
conducted outside of the United States. No human cloning will be
conducted in the United States.
The secondary mission of Reprocell Technologies is to develop and apply embryonic stem cell technologies for the
treatment of various diseases (diabetes, cancer, hematological,
articular and bowel diseases, degenerative diseases of nervous system,
different kinds of injuries, diseases of connective tissue and immune
system, including AIDS, chronic infections and sepsis) and conditions
(premature aging, male and female climax, involution and asthenic
syndromes cachexia, etc.)
tertiary mission of Reprocell Technologies is to apply propriety technology on
embryo cryopreservation. This technology will be applied in assisting
women to have access to a reliable oocyte cryopreservation regimen.
Similarly, Reprocell Technologies is aiming in establishing oocyte banks with
cryopreserved oocytes obtained from healthy women with known genetic
characteristics to be used in oocyte donation programs worldwide.
is currently working with a number of extremely reputable companies
internationally to develop and employ its technologies to all interested
parties worldwide. Reprocell Technologies through its strengths in the biotechnology
arena will remain a strong competitor and a leader in its field.